Self-Adjuvanting, Needle-Free Nanoparticle Vaccine Platform for Next-Generation Respiratory Vaccines

Description

This technology is a functionalized graphene oxide nanoparticle platform designed to deliver protein antigens efficiently to the immune system, particularly through intranasal administration. When administered intranasally, antigen-loaded nanoparticles stimulate both mucosal and systemic immunity, closely mimicking natural infection while maintaining a strong safety profile.

Respiratory diseases like influenza and emerging viral infections remain a major global health challenge, causing millions of infections and significant mortality each year. There is a clear need for a new generation of virus-independent, safe, and efficient intranasal vaccines that can induce broad cross-protection against respiratory diseases like influenza. Our nanoparticle platform is intended to address these needs by providing a self-adjuvanted system with high antigen-loading capacity that can be prepared through a simple mixing approach.

Benefits

High Antigen-Loading Capacity: The ultra-large surface area and high aspect ratio of the 2-D graphene oxide nanosheets allow for high-density antigen association
Needle-Free: The needle-free intranasal route offers superior advantages over traditional injectables, including easier administration, higher recipient acceptance, and the avoidance of biohazardous sharps waste
Self-Adjuvanting System: GO-PEI nanoparticles intrinsically activate immune cells, reducing reliance on external adjuvants and simplifying formulation.
Adaptable Design: The platform is highly flexible and can be adapted to deliver antigens for a wide range of pathogens, including various viruses (such as SARS-CoV-2, HIV, and Zika).
Simplified Manufacturing: The invention utilizes a facile mixing and adsorption approach for preparation, avoiding the complicated and lengthy covalent conjugation procedures required by other nanoparticle technologies.